Results 251 to 260 of about 31,026,669 (309)

Real-World Experience With Lenacapavir and/or Fostemsavir as Emerging Therapies for the Management of Multidrug-Resistant HIV-1 in Southeastern France. [PDF]

J Med Virol
Boujamline S, Boschi C, Bes-Barlandier H, Tomei C, Menard A, Mokhtari S, Ravaux I, Belkhir Y, Neant N, Solas C, Colson P, Million M.   +11 more
europepmc   +1 more source

Structural basis of diverse substrate recruitment by the HIV-1 Vpr-hijacked CRL4(VprBP) E3 ligase. [PDF]

PLoS Pathog
Wang D, Ding W, Xu J, Li R, Cairoli T, Liu Q, Zhu Y, Xiang Y.   +7 more
europepmc   +1 more source

Searching for a HIV-1 Cure. [PDF]

Theranostics
Zhang C, Chaudhary BN, Ali MU, Heser MG, Patel SS, Du X, Dey SS, Mosley RL, Panja S, Gendelman HE.   +9 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Maturation of HIV-1

Science, 2021
Structural transformation of HIV-1 matrix during virus maturation promotes ...
Yuta, Hikichi, Eric O, Freed
openaire   +2 more sources

Neutralization of HIV-1

AIDS Research and Human Retroviruses, 1994
A Workshop on Neutralization of HIV-1: Technology and reagents for analysis of prophylactic vaccines clinical trials, sponsored by the Food and Drug Administration (FDA) and the Division of AIDS, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), was held on April 19–20, 1993, in Bethesda, Maryland. This
H, Golding, M P, D'Souza, J, Bradac, B, Mathieson, P, Fast   +4 more
openaire   +2 more sources

HIV-1 superinfection

Journal of Allergy and Clinical Immunology, 2003
During the past year, a number of reports have described HIV-1 superinfection in human subjects, defined as the reinfection of an individual with a second heterologous strain of HIV-1. These reports have challenged the assumption that HIV-1-specific immune responses generated during primary infection are protective against subsequent infection and have
Todd M, Allen, Marcus, Altfeld
openaire   +2 more sources